Safety considerations Researchers are monitoring for: Adverse events Potential safety signals Discontinuation rates Impacts on cardiovascular disease, heart failure, and sleep apnea Changes in blood pressure and HbA1c As with any emerging therapy, more data from Phase 3 trials will be needed to fully understand risk versus benefit
The following antibodies were used: anti-GAPDH (32233, Santa Cruz Biotechnology), rabbit anti-FLAG (F7425, Sigma-Aldrich/Merck) or M2 (F3165, Sigma-Aldrich/Merck), anti-LC3B (L7543, Sigma-Aldrich/Merck), anti-WIPI2 (purified mouse IgG clone 2A2 from the Tooze lab), anti-GFP (A11122, Thermo Fisher Scientific), anti-C16orf70 (ab181987, Abcam), anti-ATG16L1 (D6D5, Cell Signaling Technology), antiBeclin 1 (D40C5, Cell Signaling Technology), anti-ATG7 (D12B11 Cell Signaling Technology), anti-HA (C29F4, Cell Signaling Technology), and anti-BCAS3 (ab71162, Abcam)
In the retraction notes, Alhakamy and his coauthors acknowledge the duplicate images and claimed that they had been reused by mistake
Patients were randomized to receive treatment with placebo (N=56), QSYMIA 7.5 mg/46 mg (N=54), or QSYMIA 15 mg/ 92 mg (N=113) in a 1:1:2 ratio
Layering medications on top of each other
